4-(1H-1,3-Benzodiazol-2-yl)benzonitrile - CAS 4110-15-0
Catalog: |
BB061557 |
Product Name: |
4-(1H-1,3-Benzodiazol-2-yl)benzonitrile |
CAS: |
4110-15-0 |
Synonyms: |
4-(1H-Benzo[d]imidazol-2-yl)benzonitrile; 4-(1h-benzimidazol-2-yl)benzonitrile; 4-(1H-1,3-benzodiazol-2-yl)benzonitrile; 2-(4-Cyanophenyl)benzimidazole; 2-(4-cyanophenyl)-1h-benzimidazole |
IUPAC Name: | 4-(1H-benzimidazol-2-yl)benzonitrile |
Molecular Weight: | 219.24 |
Molecular Formula: | C14H9N3 |
Canonical SMILES: | C1=CC=C2C(=C1)NC(=N2)C3=CC=C(C=C3)C#N |
InChI: | InChI=1S/C14H9N3/c15-9-10-5-7-11(8-6-10)14-16-12-3-1-2-4-13(12)17-14/h1-8H,(H,16,17) |
InChI Key: | INIBMZLOCLDDMA-UHFFFAOYSA-N |
References: | An, W.K.,et.al. Catal. Sci. Technol., 10, 5171-5180, (2020). |
GHS Hazard Statement: | H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
CN-109456273-A | The method of benzenecarboximidamide class compound synthesis benzimidazole compound is used in microwave method water phase | 20181206 |
CN-109468659-A | The method of room temperature synthesizing benzimidazole under the conditions of electrocatalytic method water phase | 20181206 |
CN-109180590-A | A method of Benzoheterocyclic compounds are quickly prepared using physical grinding method under room temperature solvent-free | 20180929 |
WO-2020033359-A1 | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases | 20180806 |
US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | 20180806 |
US-2020299244-A1 | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases | 20180806 |
US-2021061769-A1 | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases | 20180806 |
BR-112021002165-A2 | compound, pharmaceutical composition, and, methods of treating a neurodegenerative disease and cognitive impairment associated with aging and neuroinflammation. | 20180806 |
US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | 20180806 |
US-2021300877-A1 | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases | 20180806 |
PMID | Publication Date | Title | Journal |
21202542 | 20080507 | 4-(1H-Benzimidazol-2-yl)benzonitrile | Acta crystallographica. Section E, Structure reports online |
Complexity: | 311 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 219.0796473 |
Formal Charge: | 0 |
Heavy Atom Count: | 17 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 219.0796473 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 52.5Ų |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 3 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Other Building Blocks
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS